Summary
Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2016’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)
- The report reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Deep Vein Thrombosis (DVT) therapeutics and enlists all their major and minor projects
- The report assesses Deep Vein Thrombosis (DVT) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3SBio Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Generex Biotechnology Corporation
Laboratorios Farmaceuticos Rovi, S.A.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Deep Vein Thrombosis (DVT) Overview 7
Therapeutics Development 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9
Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10
Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 11
Deep Vein Thrombosis (DVT) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Deep Vein Thrombosis (DVT) - Products under Development by Companies 15
Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 16
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 17
3SBio Inc. 17
Bristol-Myers Squibb Company 18
F. Hoffmann-La Roche Ltd. 19
Generex Biotechnology Corporation 20
Laboratorios Farmaceuticos Rovi, S.A. 21
Deep Vein Thrombosis (DVT) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Antisense RNAi Oligonucleotide for DVT - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
apixaban - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ARC-15105 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
enoxaparin sodium - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
fondaparinux sodium - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Hematological Disorders and Cancer - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TRX-1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Deep Vein Thrombosis (DVT) - Recent Pipeline Updates 41
Deep Vein Thrombosis (DVT) - Dormant Projects 49
Deep Vein Thrombosis (DVT) - Discontinued Products 50
Deep Vein Thrombosis (DVT) - Product Development Milestones 51
Featured News & Press Releases 51
Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 51
Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 52
Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis 53
Nov 30, 2015: New Data from Bayer’s Portfolio in Thrombosis to be Presented at ASH 2015 53
Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 54
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 57
May 04, 2015: Bayer’s Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis 57
Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 58
Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 59
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63
List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2016 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc., H1 2016 17
Deep Vein Thrombosis (DVT) - Pipeline by Bristol-Myers Squibb Company, H1 2016 18
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H1 2016 20
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Deep Vein Thrombosis (DVT) Therapeutics - Recent Pipeline Updates, H1 2016 41
Deep Vein Thrombosis (DVT) - Dormant Projects, H1 2016 49
Deep Vein Thrombosis (DVT) - Discontinued Products, H1 2016 50
List of Figures
Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2016 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Mechanism of Actions, H1 2016 25
Number of Products by Stage and Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
